| Literature DB >> 27501139 |
A Rajeswari1, K V Vimalnath1, H D Sarma2, Priyalata Shetty1, Shahiralm Khan Mohammed1, Jitendra Nuwad3, Sudipta Chakraborty4, Ashutosh Dash1.
Abstract
In the present article we describe a systematic approach pursued for the synthesis of (32)P-labeled hydroxyapatite (HA) microparticles (1-10µm size range) using no carrier added (NCA) (32)P produced in a nuclear reactor and animal evaluation of its utility as an expected viable radiopharmaceutical for the treatment of pain intensive arthrosis. NCA (32)P was produced via the (32)S(n,p)(32)P route in nuclear reactor with high radionuclidic purity (99.95±0.01%, n=5). Phosphorus-32-labeled hydroxyapatite microparticles (1-10µm size range) were synthesized with high radiochemical purity (99.0±0.3% n=12) under optimized conditions and the formulation showed excellent in vitro stability in saline as well as in rat serum. Intra-articular administration of the radiolabeled particles in the knee joints of normal Wistar rats showed near-complete retention of activity within the synovial cavity upto 1 month post-administration. The radiochemical formulation thus demonstrated promising features as a radiopharmaceutical for treatment of arthritis with excellent logistic advantage for shipment to sites distant from the production facility thanks to the suitable nuclear decay properties of (32)P.Entities:
Keywords: Arthritis; Hydroxyapatite (HA) microparticles; NCA (32)P; Radiation synovectomy; Radiolabeling
Mesh:
Substances:
Year: 2016 PMID: 27501139 DOI: 10.1016/j.apradiso.2016.07.022
Source DB: PubMed Journal: Appl Radiat Isot ISSN: 0969-8043 Impact factor: 1.513